Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.

Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC.

Oral Oncol. 2019 Aug;95:127-135. doi: 10.1016/j.oraloncology.2019.06.016. Epub 2019 Jun 20.


Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV-and HPV+ Head and Neck Cancers to TNF╬▒, TRAIL, and Radiation Therapy.

Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-3802. [Epub ahead of print]


Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?

Ye W, Schmitt NC.

Ann Transl Med. 2019 Mar;7(Suppl 1):S14. doi: 10.21037/atm.2019.01.46. No abstract available.


Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.

Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H.

Head Neck. 2018 Dec;40(12):E100-E106. doi: 10.1002/hed.25392. Epub 2018 Nov 26.


Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC.

Oncoimmunology. 2018 Aug 1;7(9):e1471440. doi: 10.1080/2162402X.2018.1471440. eCollection 2018.


T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.

Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, Lin Y, Ferris RL.

Oncoimmunology. 2018 Aug 24;7(11):e1494112. doi: 10.1080/2162402X.2018.1494112. eCollection 2018.


Radiation-Associated Sarcoma of the Neck: Case Series and Systematic Review.

Williams L, Tmanova L, Mydlarz WK, Page B, Richmon JD, Quon H, Schmitt NC.

Ann Otol Rhinol Laryngol. 2018 Oct;127(10):735-740. doi: 10.1177/0003489418789966. Epub 2018 Jul 26. Review.


Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Schmitt NC, Kang H, Sharma A.

Oral Oncol. 2017 Nov;74:40-48. doi: 10.1016/j.oraloncology.2017.09.008. Epub 2017 Sep 21. Review.


Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.

Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC.

Cancer Immunol Res. 2017 Dec;5(12):1141-1151. doi: 10.1158/2326-6066.CIR-17-0235. Epub 2017 Nov 2.


Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.

Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL.

Cancer. 2017 Nov 15;123(22):4382-4390. doi: 10.1002/cncr.30966. Epub 2017 Sep 26.


PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.


Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.

Schmitt NC, Page BR.

Int J Audiol. 2018 Sep;57(sup4):S49-S54. doi: 10.1080/14992027.2017.1353710. Epub 2017 Jul 20. Review.


Putting T cells to work-outsourcing neoantigen detection in head and neck cancers?

Xiao R, Van Waes C, Schmitt NC.

Oral Dis. 2017 Oct;23(7):820-821. doi: 10.1111/odi.12604. Epub 2016 Nov 28. No abstract available.


Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.


Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.

Davis RJ, Ferris RL, Schmitt NC.

Cancers Head Neck. 2016 Oct 1;1:12. doi: 10.1186/s41199-016-0013-x. eCollection 2016. Review.


Cervical Osteomyelitis After Pharyngeal Surgical Manipulation.

Govil N, Schmitt NC, Kim S.

JAMA Otolaryngol Head Neck Surg. 2016 Nov 1;142(11):1130. doi: 10.1001/jamaoto.2016.1837. No abstract available.


Characterization of human papillomavirus antibodies in individuals with head and neck cancer.

Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T.

Cancer Epidemiol. 2016 Jun;42:46-52. doi: 10.1016/j.canep.2016.03.003. Epub 2016 Mar 21.


A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.

Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S.

JAMA Otolaryngol Head Neck Surg. 2016 May 1;142(5):489-95. doi: 10.1001/jamaoto.2015.3930.


Intraoperative identification of the human communicating nerve during thyroidectomy.

Hodnett BL, Schmitt NC, Thirumala PD, Duvvuri U.

J Surg Case Rep. 2015 Dec 13;2015(12). pii: rjv154. doi: 10.1093/jscr/rjv154.


Early T Stage Salivary Duct Carcinoma: Outcomes and Implications for Patient Counseling.

Schmitt NC, Sharma A, Gilbert MR, Kim S.

Otolaryngol Head Neck Surg. 2015 Nov;153(5):795-8. doi: 10.1177/0194599815601659. Epub 2015 Aug 25.


STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.

Schmitt NC, Trivedi S, Ferris RL.

Mol Cancer Ther. 2015 Sep;14(9):2103-11. doi: 10.1158/1535-7163.MCT-15-0305. Epub 2015 Jul 3.


Antibiotic Prophylaxis in Patients Undergoing Head and Neck Free Flap Reconstruction.

Mitchell RM, Mendez E, Schmitt NC, Bhrany AD, Futran ND.

JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1096-103. doi: 10.1001/jamaoto.2015.0513.


Transoral robotic surgery for oropharyngeal squamous cell carcinoma.

Schmitt NC, Duvvuri U.

Curr Opin Otolaryngol Head Neck Surg. 2015 Apr;23(2):127-31. doi: 10.1097/MOO.0000000000000136. Review.


Superior laryngeal nerve monitoring using laryngeal surface electrodes and intraoperative neurophysiological monitoring during thyroidectomy.

Hodnett BL, Schmitt NC, Clayburgh DR, Burkowsky A, Balzer J, Thirumala PD, Duvvuri U.

Clin Anat. 2015 May;28(4):460-6. doi: 10.1002/ca.22487. Epub 2014 Nov 25.


Immune biomarkers of anti-EGFR monoclonal antibody therapy.

Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL.

Ann Oncol. 2015 Jan;26(1):40-7. doi: 10.1093/annonc/mdu156. Epub 2014 Jul 4. Review.


Osteopontin does not mitigate cisplatin ototoxicity or nephrotoxicity in adult mice.

Schmitt NC, Rubel EW.

Otolaryngol Head Neck Surg. 2013 Oct;149(4):614-20. doi: 10.1177/0194599813498218. Epub 2013 Jul 24.


Pathology quiz case 1. Diagnosis: laryngeal rhabdomyosarcoma, embryonal subtype.

Hsia JC, Schmitt NC, Hoch B, Moe KS.

Arch Otolaryngol Head Neck Surg. 2011 Jun;137(6):635, 638-9. doi: 10.1001/archoto.2011.71-a. No abstract available.


Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate.

Schmitt NC, Rubel EW, Nathanson NM.

J Neurosci. 2009 Mar 25;29(12):3843-51. doi: 10.1523/JNEUROSCI.5842-08.2009.


Tributylphosphate extraction behavior of bismuthate-oxidized americium.

Mincher BJ, Martin LR, Schmitt NC.

Inorg Chem. 2008 Aug 4;47(15):6984-9. doi: 10.1021/ic800667h. Epub 2008 Jul 2.


Supplemental Content

Loading ...
Support Center